Back to today’s briefing

Story perspectives

Former CEO Accused of Insider Trading Amid Vaccine Contamination

1/15/2026

30 2 Full Breakdown

Summary

Story summary

The New York attorney general accuses Robert Kramer, former CEO of Emergent BioSolutions, of insider trading.
Kramer sold over $10 million in Emergent stock after learning of contamination that rendered millions of doses unusable, before public disclosure.
Emergent BioSolutions had two contracts totaling $261 million to produce vaccines for AstraZeneca under Operation Warp Speed.
The company also held contracts with Johnson & Johnson.

1 of 1

Story summary

The New York attorney general accuses Robert Kramer, former CEO of Emergent BioSolutions, of insider trading.
Kramer sold over $10 million in Emergent stock after learning of contamination that rendered millions of doses unusable, before public disclosure.
Emergent BioSolutions had two contracts totaling $261 million to produce vaccines for AstraZeneca under Operation Warp Speed.
The company also held contracts with Johnson & Johnson.